196 related articles for article (PubMed ID: 36281134)
1. Humoral immune response against BNT162b2 mRNA COVID-19 vaccine in patients with rheumatic disease undergoing immunosuppressive therapy: A Japanese monocentric study.
Sugihara K; Wakiya R; Kameda T; Shimada H; Nakashima S; Kato M; Miyagi T; Ushio Y; Mizusaki M; Mino R; Chujo K; Nomura Y; Inoo M; Kadowaki N; Dobashi H
Medicine (Baltimore); 2022 Oct; 101(42):e31288. PubMed ID: 36281134
[TBL] [Abstract][Full Text] [Related]
2. Immunogenicity against the BNT162b2 mRNA COVID-19 Vaccine in Rheumatic Disease Patients Receiving Immunosuppressive Therapy.
Sugihara K; Wakiya R; Shimada H; Kameda T; Nakashima S; Kato M; Miyagi T; Mizusaki M; Mino R; Nomura Y; Inoo M; Kadowaki N; Dobashi H
Intern Med; 2022 Jul; 61(13):1953-1958. PubMed ID: 35466168
[TBL] [Abstract][Full Text] [Related]
3. Immunosuppressive therapy and humoral response to third mRNA COVID-19 vaccination with a six-month interval in rheumatic disease patients.
Kashiwado Y; Kimoto Y; Ohshima S; Sawabe T; Irino K; Nakano S; Hiura J; Yonekawa A; Wang Q; Doi G; Ayano M; Mitoma H; Ono N; Arinobu Y; Niiro H; Hotta T; Kang D; Shimono N; Akashi K; Takeuchi T; Horiuchi T
Rheumatology (Oxford); 2024 Mar; 63(3):725-733. PubMed ID: 37289506
[TBL] [Abstract][Full Text] [Related]
4. Humoral and cellular immune response to mRNA SARS-CoV-2 BNT162b2 vaccine in adolescents with rheumatic diseases.
Udaondo C; Cámara C; Miguel Berenguel L; Alcobendas Rueda R; Muñoz Gómez C; Millán Longo C; Díaz-Delgado B; Falces-Romero I; Díaz Almirón M; Ochando J; Méndez-Echevarría A; Remesal Camba A; Calvo C
Pediatr Rheumatol Online J; 2022 Aug; 20(1):64. PubMed ID: 35964130
[TBL] [Abstract][Full Text] [Related]
5. Factors associated with anti-SARS-CoV-2 spike antibody titers after a second BNT162b2 mRNA COVID-19 vaccination in Japanese hemodialysis patients.
Hirai K; Shimotashiro M; Sonoda T; Okumura T; Ookawara S; Morishita Y
Clin Exp Nephrol; 2022 Sep; 26(9):925-932. PubMed ID: 35426594
[TBL] [Abstract][Full Text] [Related]
6. Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study.
Furer V; Eviatar T; Zisman D; Peleg H; Paran D; Levartovsky D; Zisapel M; Elalouf O; Kaufman I; Meidan R; Broyde A; Polachek A; Wollman J; Litinsky I; Meridor K; Nochomovitz H; Silberman A; Rosenberg D; Feld J; Haddad A; Gazzit T; Elias M; Higazi N; Kharouf F; Shefer G; Sharon O; Pel S; Nevo S; Elkayam O
Ann Rheum Dis; 2021 Oct; 80(10):1330-1338. PubMed ID: 34127481
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of COVID-19 mRNA vaccination in patients with autoimmune disorders: humoral and cellular immune response.
Filippini F; Giacomelli M; Bazzani C; Fredi M; Semeraro P; Tomasi C; Franceschini F; Caruso A; Cavazzana I; Giagulli C
BMC Med; 2023 Jun; 21(1):210. PubMed ID: 37316832
[TBL] [Abstract][Full Text] [Related]
8. SARS-CoV-2 spike protein antibody titers 6 months after SARS-CoV-2 mRNA vaccination among patients undergoing hemodialysis in Japan.
Kanai D; Wakui H; Haze T; Azushima K; Kinguchi S; Tsukamoto S; Kanaoka T; Urate S; Toya Y; Hirawa N; Kato H; Watanabe F; Hanaoka K; Hanaoka M; Mitsuhashi H; Yamaguchi S; Ohnishi T; Tamura K
Clin Exp Nephrol; 2022 Oct; 26(10):988-996. PubMed ID: 35751753
[TBL] [Abstract][Full Text] [Related]
9. Differences in IgG Antibody Responses following BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines.
Montoya JG; Adams AE; Bonetti V; Deng S; Link NA; Pertsch S; Olson K; Li M; Dillon EC; Frosch DL
Microbiol Spectr; 2021 Dec; 9(3):e0116221. PubMed ID: 34756093
[TBL] [Abstract][Full Text] [Related]
10. Effect of Different Disease-Modifying Therapies on Humoral Response to BNT162b2 Vaccine in Sardinian Multiple Sclerosis Patients.
Pitzalis M; Idda ML; Lodde V; Loizedda A; Lobina M; Zoledziewska M; Virdis F; Delogu G; Pirinu F; Marini MG; Mingoia M; Frau J; Lorefice L; Fronza M; Carmagnini D; Carta E; Orrù V; Uzzau S; Solla P; Loi F; Devoto M; Steri M; Fiorillo E; Floris M; Zarbo IR; Cocco E; Cucca F
Front Immunol; 2021; 12():781843. PubMed ID: 34956211
[TBL] [Abstract][Full Text] [Related]
11. The persistence of anti-Spike antibodies following two SARS-CoV-2 vaccine doses in patients on immunosuppressive therapy compared to healthy controls-a prospective cohort study.
Christensen IE; Jyssum I; Tveter AT; Sexton J; Tran TT; Mjaaland S; Kro GB; Kvien TK; Warren DJ; Jahnsen J; Munthe LA; Haavardsholm EA; Vaage JT; Grødeland G; Lund-Johansen F; Jørgensen KK; Syversen SW; Goll GL; Provan SA
BMC Med; 2022 Oct; 20(1):378. PubMed ID: 36199139
[TBL] [Abstract][Full Text] [Related]
12. Immunogenicity and safety of the mRNA-based BNT162b2 vaccine in systemic autoimmune rheumatic diseases patients.
Pri-Paz Basson Y; Tayer-Shifman OE; Naser R; Tartakover Matalon S; Kimhi O; Gepstein R; Halperin T; Ziv-Baran T; Ziv A; Parikh R; Kivity S; Levy Y
Clin Rheumatol; 2022 Dec; 41(12):3879-3885. PubMed ID: 36050514
[TBL] [Abstract][Full Text] [Related]
13. Type of mRNA COVID-19 vaccine and immunomodulatory treatment influence humoral immunogenicity in patients with inflammatory rheumatic diseases.
Raptis CE; Berger CT; Ciurea A; Andrey DO; Polysopoulos C; Lescuyer P; Maletic T; Riek M; Scherer A; von Loga I; Safford J; Lauper K; Möller B; Vuilleumier N; Finckh A; Rubbert-Roth A
Front Immunol; 2022; 13():1016927. PubMed ID: 36311791
[TBL] [Abstract][Full Text] [Related]
14. A prospective multicenter study assessing humoral immunogenicity and safety of the mRNA SARS-CoV-2 vaccines in Greek patients with systemic autoimmune and autoinflammatory rheumatic diseases.
Tzioufas AG; Bakasis AD; Goules AV; Bitzogli K; Cinoku II; Chatzis LG; Argyropoulou OD; Venetsanopoulou AI; Mavrommati M; Stergiou IE; Pezoulas V; Voulgari PV; Katsimpari C; Katechis S; Gazi S; Katsifis G; Sfontouris CI; Georgountzos AI; Liossis SN; Papagoras C; Fotiadis DI; Skopouli FN; Vlachoyiannopoulos PG; Moutsopoulos HM
J Autoimmun; 2021 Dec; 125():102743. PubMed ID: 34757289
[TBL] [Abstract][Full Text] [Related]
15. Depressive symptoms predict antibody titers after a second dose of the SARS-CoV-2 BNT162b2 vaccine among hospital workers in Japan.
Kaneko H; Tsuboi H
Brain Behav Immun; 2023 Jan; 107():414-418. PubMed ID: 36116693
[TBL] [Abstract][Full Text] [Related]
16. BNT162b2 vaccine-induced humoral and cellular responses against SARS-CoV-2 variants in systemic lupus erythematosus.
Moyon Q; Sterlin D; Miyara M; Anna F; Mathian A; Lhote R; Ghillani-Dalbin P; Breillat P; Mudumba S; de Alba S; Cohen-Aubart F; Haroche J; Pha M; Boutin THD; Chaieb H; Flores PM; Charneau P; Gorochov G; Amoura Z
Ann Rheum Dis; 2022 Apr; 81(4):575-583. PubMed ID: 34607791
[TBL] [Abstract][Full Text] [Related]
17. Antibody response to SARS-CoV-2 mRNA vaccines in patients with rheumatic diseases in Japan: Interim analysis of a multicentre cohort study.
Kashiwado Y; Kimoto Y; Sawabe T; Irino K; Nakano S; Hiura J; Wang Q; Kawano S; Ayano M; Mitoma H; Ono N; Arinobu Y; Niiro H; Hotta T; Kang D; Akashi K; Ohshima S; Takeuchi T; Horiuchi T
Mod Rheumatol; 2023 Mar; 33(2):367-372. PubMed ID: 35411376
[TBL] [Abstract][Full Text] [Related]
18. Healthcare Workers in South Korea Maintain a SARS-CoV-2 Antibody Response Six Months After Receiving a Second Dose of the BNT162b2 mRNA Vaccine.
Choi JH; Kim YR; Heo ST; Oh H; Kim M; Lee HR; Yoo JR
Front Immunol; 2022; 13():827306. PubMed ID: 35173736
[TBL] [Abstract][Full Text] [Related]
19. Antibody Responses to the BNT162b2 mRNA Vaccine in Healthcare Workers in a General Hospital in Japan: A Comparison of Two Assays for Anti-spike Protein Immunoglobulin G.
Hibino M; Watanabe S; Kamada R; Tobe S; Maeda K; Horiuchi S; Kondo T
Intern Med; 2022 Mar; 61(6):811-819. PubMed ID: 34980798
[TBL] [Abstract][Full Text] [Related]
20. Seroprevalence of SARS-CoV-2 spike IgG antibodies after the second BNT162b2 mRNA vaccine in Japanese kidney transplant recipients.
Hamaya T; Hatakeyama S; Yoneyama T; Tobisawa Y; Kodama H; Fujita T; Murakami R; Fujita N; Okamoto T; Yamamoto H; Yoneyama T; Hashimoto Y; Saitoh H; Narumi S; Tomita H; Ohyama C
Sci Rep; 2022 Apr; 12(1):5876. PubMed ID: 35393481
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]